



Norwegian Cardiologists Use Breakthrough Technology to Study Heart Remodeling After Valve Replacement in Patients With Blue-Baby Syndrome

Thursday, April 21, 2011

SEATTLE, WASHINGTON--(Marketwire - April 21, 2011) - VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX VENTURE:VPT) (PINK SHEETS:VPTDF) – A leading Norwegian pediatric cardiologist said the medical technology developed by VentriPoint has opened a new window to monitoring the remodeling of the right heart after pulmonary valve replacement.

Dr. Henrik Brun, a cardiologist at Norway's premier children's hospital called Oslo University Hospital in the capital city of Oslo, will be presenting a study designed to assess VentriPoint Medical System(VMS™) as a monitoring tool.

"We have been using the VMS™ for three months with promising results," said Dr. Henrik Brun. "It is time to tell other paediatric cardiologists about our first experience and what we hope to achieve; particularly for the follow-up of Tetralogy of Fallot (a heart disease often referred to as 'blue-baby syndrome') patients that we have studied using the VMS™ imaging process."

To that end Dr. Brun will be speaking about "Knowledge based reconstruction: A New 3D Echocardiology Concept" at a cardiology meeting in Norway on April 27th. Knowledge based reconstruction is the fundamental technology around which the VMS™ system is built.

Dr. Brun and Dr. Christian Neukamm have been using the VMS™ since December of 2010 as part of a project to evaluate right ventricular function in patients that have had a pulmonary valve replacement using a Perimount® bovine pericardial tissue valve.

The Rikshospitalet University Hospital is a national reference hospital responsible for introducing and developing new medical examination methods, treatment methods and follow-ups. It conducts more than 50 per cent of the total medical research in Norwegian medical centres.

In other news, VentriPoint also announces that, pending TSX Venture Exchange approval, it intends to issue 441,088 common shares in the capital of VentriPoint (the "Commons Shares") to holders of secured debentures of the Corporation (the "Secured Debentures") in satisfaction of annual interest due on the Secured Debentures in accordance with the terms of the Secured Debentures. The Common Shares will be issued at a deemed price (10-day average on interest due date) of \$0.148 per share to the holders of the Secured Debentures for interest due totaling \$65,281 and will have a hold period of four months from the date of issuance in accordance with applicable securities legislation.

About VentriPoint Diagnostics Ltd:

VentriPoint creates diagnostic systems to monitor patients with heart disease, the number one cause of death in developed countries. The VMS is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application with additional applications in process to enable monitoring of all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a \$10 Billion market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS diagnostic tool and a 510(k) submission is currently being reviewed by the U.S. Federal Drug Administration. For further information about VentriPoint go to www.ventripoint.com.

Cautionary Note Regarding Forward-Looking Statements - Certain statements contained herein constitute forward-looking statements, including statements concerning the anticipated closing date of the Offering and the anticipated use of proceeds. We believe the expectations reflected in those forward-looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included herein should not be unduly relied upon. Closing could be delayed if VentriPoint cannot obtain necessary regulatory approvals within anticipated timelines and will not be completed unless certain conditions customary for transactions of this kind are satisfied. The forward-looking statements included in this press release are made as of the date of this press release and VentriPoint disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Ventripoint Diagnostics .
George Adams
President & CEO
Ph: (403) 283-0221
Fax: (403) 283-2309
info@ventripoint.com
www.ventripoint.com

The Howard Group Inc.
Peter Weichler/Dave Burwell
Investor Relations
Toll Free: 1-888-221-0915
Phone: (403) 221-0915
Info@howardgroupinc.com
www.howardgroupinc.com